Analyses and Correlation of Pathologic and Ocular Cutaneous Changes in Murine Graft versus Host Disease

Robert B. Levy 1,*, Hazem M. Mousa 2, Casey O. Lightbourn 1, Eric J. Shiuey 2, David Latoni 2, Stephanie Duffort 1, Ryan Flynn 3, Jing Du 3, Henry Barreras 1, Michael Zaiken 3, Katelyn Paz 3, Bruce R. Blazar 3  and Victor L. Perez 2,3

1 Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA; col8@med.miami.edu (C.O.L.); sduffort@med.miami.edu (S.D.); hbarreras@med.miami.edu (H.B.)
2 School of Medicine, Duke University, Durham, NC 27708, USA; hm146@duke.edu (H.M.M.); ericshiuey@gmail.com (E.J.S.); david.latoni_morales@tufts.edu (D.L.)
3 Department of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA; rflynn85@gmail.com (R.F.); jing.du@northwestern.edu (J.D.); zaik002@umn.edu (M.Z.); katelyngoodman2@gmail.com (K.P.); blaza001@umn.edu (B.R.B.)

* Correspondence: rlevy@med.Miami.edu (R.B.L.); victor.perez.quinones@duke.edu (V.L.P.)

Abstract: Graft versus host disease (GVHD) is initiated by donor allo-reactive T cells activated against recipient antigens. Chronic GVHD (cGVHD) is characterized by immune responses that may resemble autoimmune features present in the scleroderma and Sjogren’s syndrome. Unfortunately, ocular involvement occurs in approximately 60–90% of patients with cGVHD following allo-hematopoietic stem cell transplants (aHSCT). Ocular GVHD (oGVHD) may affect vision due to ocular adnexa damage leading to dry eye and keratopathy. Several other compartments including the skin are major targets of GVHD effector pathways. Using mouse aHSCT models, the objective was to characterize cGVHD associated alterations in the eye and skin to assess for correlations between these two organs. The examination of multiple models of MHC-matched and MHC-mismatched aHSCT identified a correlation between ocular and cutaneous involvement accompanying GVHD. Studies detected a “positive” correlation, i.e., when cGVHD-induced ocular alterations were observed, cutaneous compartment alterations were also observed. When no or minimal ocular signs were detected, no or minimal skin changes were observed. In total, these findings suggest underlying cGVHD-inducing pathological immune mechanisms may be shared between the eye and skin. Based on the present observations, we posit that when skin involvement is present in aHSCT patients with cGVHD, the evaluation of the ocular surface by an ophthalmologist could potentially be of value.

Keywords: ocular GVHD; cutaneous GVHD; correlation; pathology; ocular immune response; inflammation

1. Introduction

Allogeneic hematopoietic stem cell transplantation (aHSCT) has become the standard of care for many hematopoietic malignancies and genetic disorders. Despite advances in achieving allo-engraftment, graft versus host disease (GVHD) remains a major obstacle to the more widespread usage of this cellular therapy [1–5]. While advances in GVHD prophylaxis and treatment have resulted in higher survival rates post-HSCT, patient quality of life is compromised in part as a result of ocular complications, such as dry eye, leading to loss of visual acuity and, in some cases, blindness [6–10]. Unfortunately, it is estimated that ocular GVHD is present in 60–90% of patients with chronic GVHD manifestation [11]. Moreover, dermatologic manifestations are also common and significantly affect patients by causing skin, often scleroderma-like, lesions and promoting infection, thereby limiting the patient’s ability to function on a daily basis [12,13].
Notably, in murine experimental aHSCT models, we and others have identified ophthalmic manifestations that may correlate with dermatologic changes during the course of systemic chronic GVHD [14–19]. To date, we are not aware of reports that have evaluated and compared ocular changes and cutaneous alterations in controlled experiments using established mouse models of GVHD. Accordingly, we posited that these two GVHD target tissues may share similar immune mechanisms leading to correlate damage and clinical manifestations. To rigorously test this hypothesis, in this study we examined multiple well-defined experimental GVHD mouse models. This included experiments to examine for correlations in animals undergoing therapeutic treatment using post-transplant cyclophosphamide (PTCy) as a single agent for GVHD prophylaxis, which others and our labs have demonstrated to ameliorate GVHD [20,21].

To address these questions, allogeneic HSCT was performed using mouse models of MHC-matched and MHC-mismatched donor/recipient combinations. In MHC-matched aHSCT recipients, skin changes represented by the thickening of the keratinized epithelium and infiltration of the dermis by mononuclear inflammatory cells were accompanied by ocular manifestations represented by lid margin edema and corneal superficial punctate keratopathy in recipients that had increased clinical scores. A correlation between skin and ocular manifestations was also observed using the MHC mismatched (H2b → H2k and H2b → H2d) models. Interestingly, one of the MHC-mismatched transplant combinations (H2b → H2d) exhibited both skin and ocular changes. In contrast, the other combination (H2b → H2k) did not, i.e., neither skin nor ocular damage was observed.

In total, using well-established multiple pre-clinical mouse aHSCT models, we found that there were consistent and statistically significant correlations identified between the presence or absence of ophthalmic and cutaneous manifestations of GVHD. Therefore, similar to patients following aHSCT where clinical complications associated with GVHD vary, our work suggests that in mice that developed GVHD the same correlations between ocular GVHD and scleroderma may exist, and this should be taken into consideration as a potential biomarker to guide systemic and local treatment of this disease.

2. Materials and Methods

2.1. Animals

All animal studies were conducted according to protocols approved by the University of Miami, Minnesota, and Duke University’s Animal Care and Use Committees, and in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. C57Bl/6 (B6; H2b), C3H.SW (H2b), LP/J (H2b), B10.BR(H2k), BALB/c (H2d), and B10.D2 (H2d) (NCI, Taconic, or The Jackson Laboratory) and maintained at university facilities. All mice used in experiments were 8–10 weeks old, exhibited no obvious ocular surface and eyelid disease at baseline, and were fed with a standard caloric diet for their age. The animals were maintained in pathogen-free conditions at the respective University animal facilities and routinely monitored prior to all procedures until the end of the experiment.

2.2. Hematopoietic Stem Cell Transplantation (HSCT)

Major MHC-mismatched HSCT models and use of cyclophosphamide post-transplant: B6->BALB/c (H2d) received ablative conditioning with a single dose of 8.5 Gy total body irradiation (TBI, X-ray and Cesium) 1 day prior to transplant. Bone marrow (BM) cells were obtained from femurs ± tibias, and vertebrae from sex-matched B6-CD45.1 (H2b; Thy1.2) donor animals. A single-cell suspension of BM cells was prepared by flushing bones with a 21-gauge needle filtering through a 100-µm nylon mesh. T-cell depletion (TCD) of donor marrow cells was achieved via complement-mediated lysis using anti-T-cell-specific antibody HO-13-4 (hybridoma supernatant, mouse anti-Thy1.2 IgM; ATCC), anti-CD4 (clone 72.4) mAb, anti-CD8 (clone H02.2) mAb (initially provided by Dr. Bruce Blazar, University of Minnesota, Minneapolis, MN, USA), and rabbit complement (Cedarlane Laboratories, Burlington, ON, Canada). The marrow cells were incubated at 37 °C for
45 min, washed twice in RPMI, and resuspended for hematopoietic cell transplant. Marrow TCD was routinely >99%. Donor T cells were prepared from spleens obtained from B6-FoxP3rfp animals. Donor cells were stained for T cells (anti-CD4, clone RM4-5; anti-CD8, clone 53-6-7) and adjusted to $1.1 \times 10^6$ T cells per mouse prior to mixing with BM. Recipient mice were transplanted (day 0) with TCD BM ($5 \times 10^6$) and $1.1 \times 10^6$ T cells IV in a 0.2 mL volume via tail vein injection.

In some experiments, as indicated, cyclophosphamide was administered on days 3 and 4 (50 mg/kg i.p. per injection) post-transplant (i.e., PTCy) for single agent GVHD prophylaxis as previously described by us and others [20,21]. Additionally, in some experiments, transplanted mice also received TL1A-Ig (50 µg/injection × 4) and low dose IL-2 (10,000 units rhIL-2/injection × 2), following PTCy using a protocol we have previously reported to stimulate the TNFRSF25 and CD25 receptors in vivo [22,23].

B6→B10.BR recipients were conditioned with cyclophosphamide on days 3 and 2 (120 mg/kg per day intraperitoneally). On day 1, recipients received TBI by X-ray (8.3 Gy). B6 donor BM was TCD (T cell depleted) with anti-Thy1.2 monoclonal antibody (mAb), followed by a rabbit complement. Splenic T cells were purified by negative selection using anti-CD19, anti-B220, anti-CD11b, anti-CD11c, anti-TCRg/d, anti-NK1.1, and anti-TER119 antibodies and Stemcell Rapidsphere magnetic beads (StemCell Technologies, Vancouver, BC, Canada). On day 0, recipients received $10 \times 10^6$ TCD BM cells ± 70–75,000 T cells [24].

### 2.3. MHC-Matched HSCT Models

B10.D2 BM ($10 \times 10^6$) and T cells ($2.7 \times 10^6$; 2:1 CD4:CD8 ratio), purified as above, were given to Balb/c recipients conditioned with 7.5Gy TBI by X-ray (day 1). The mice were monitored daily and assessed for clinical score and skin score as described previously [25,26]. B6 (H2b) → C3H.SW (H2b) recipients were conditioned with 10.5 Gy (n = 8) using a Cs137 source 3–4 h prior to transplantation. Cell suspensions containing donor B6 bone marrow and T cells were prepared as described above for the B6→BALB/c transplants and adjusted in a serum-free medium to a concentration of $4.6 \times 10^6$/mL for intravenous (0.5 mL) injection of $2.3 \times 10^6$ T cells/mouse. LP/J (H2b) → B6 (H2b) recipients were conditioned with 8.5 Gy TBI from a Cs137 source on day 0. The mice were injected intravenously (IV) with TCD-BM ($1 \times 10^7$) with or without splenic T cells ($8 \times 10^5$).

### 2.4. Clinical Evaluation of Systemic and Ocular Graft vs. Host Disease

Systemic and cutaneous GVHD was assessed by monitoring recipients for changes in total body weight, clinical signs, and overall survival as previously described [22,26]. The clinical signs of GVHD were recorded for individual mice. Recipients at the University of Miami and Duke were scored on a scale from 0 to 2 for 6 clinical parameters. We adapted our scoring for clinical parameters—a majority of which was originally obtained from Cooke et al. [27]—to a “scale from 0 to 2 for 6 clinical parameters including diarrhea”, as described by Perez et al. [15]. The systemic parameters included were: (1) weight loss; (2) diarrhea; (3) fur texture; (4) posture; (5) alopecia; and (6) mobility. Additionally, for skin scoring performed at the University of Minnesota, cutaneous changes were scored as previously described [25].

Ocular GVHD: To monitor and score ocular clinical pathological changes, at each time-point of analysis, individual animals were evaluated and graded from 0–4 for the clinical parameters (1) eyelid and (2) corneal involvement, modified from Perez et al. [15].

### 2.5. Histology and Analyses of Corneal and Cutaneous Pathological Changes

To assess and compare the histologic findings between the GVHD and BMO groups, the microscopic examination of histology slides was performed and scaled photographs were obtained.
2.6. Details of Staining and Sectioning

Eyes and skin punch biopsy samples from the different experimental and control mice were collected and frozen into tissue blocks. Frozen tissue blocks containing the eyes were sectioned using the cryotome at the desired thickness (10–12 µm). The sections were then collected by mounting on slides. Then, the slides were left to air dry for 3–5 min after which they were stained with 0.1% Mayer’s hematoxylin (Sigma: MHS-16) for 5–10 min in a 50 mL conical tube. After rinsing with running ddH2O for 5 min, the sections were dipped in 0.5% eosin 12 times and then sequentially dipped in H2O (10 times), 50% ethanol (10 times), and 70% ethanol (10 times). The slides were then equilibrated in 95% ethanol for 30 s and 100% ethanol for 1 min, before being dipped in xylene multiple times. Finally, a coverslip was placed with Cytoseal XYL (Stephens Scientific).

2.7. Disease Comparison and Statistical Analyses

To assess for clinical disease association between ocular and skin GVHD, MHC-matched (B6 → C3H.5W) allogeneic transplant of donor bone marrow only (n = 5) and bone marrow + T cells (n = 5) was carried out. Each mouse was scored 3 times a week for ocular and systemic disease, as described previously (Section 2.4). The disease parameters were plotted as mean +/- SD to identify trends and a descriptive analysis was used to identify associations.

The histologic findings were evaluated and compared between the GVHD and BM groups; the microscopic examination of histology slides was performed and photographs were obtained. For the ocular scores, gross changes identified included (1) corneal epithelial thickening, (2) stromal thinning, and (3) vacuolization of the corneal epithelium. For the skin score, parameters identified included (1) dermal thickening, (2) epidermal thickening, and (3) loss of hair follicles. These parameters were measured and quantified across the different eye tissue harvested from transplanted animals. A Mann–Whitney non-parametric t-test was used for statistical analysis to compare the median of both BM + T disease and BMO control groups and a p-value of < 0.05 was considered significant.

A composite ocular and a composite skin histology disease score were obtained to allow testing for correlation between the different disease findings (ocular and skin). Both control (BM only) and experimental (BM + T cells) groups were grouped, and the median and interquartile range were calculated. For each of the 3 ocular and 3 skin disease parameters, the cut-off for the first quartile (Q1), the median, and the cutoff for the third quartile (Q3) were then used as the scoring cutoffs to determine the score of disease for each category. For each of the 6 parameters, scores ranged from 0–3 with a score of 0 for values within the 1st quartile, a score of 1 for values within the 2nd quartile, a score of 2 for values within the 3rd quartile, and a score of 3 for values within the 4th quartile. For each of the ocular parameters and skin parameters, the scores from each of the parameters were then added to achieve a composite score for each mouse ranging from 0–9, 1 for ocular disease and 1 for skin disease. Spearman’s rank correlation coefficient was used to determine the correlation between the calculated composite ocular and composite skin disease scores. Only mice with both ocular and skin histologic measures were included which led to a sample size of n = 8. Spearman’s r coefficient was calculated and a p-value < 0.05 (denoted by an asterisk “*”) was used to determine the significance of correlation.

3. Results

3.1. Kinetic Analysis of Changes in the Eye and Skin following Pre-Clinical MHC-Matched Allogeneic Hematopoietic Stem Cell Transplants

To investigate for a potential relationship between ocular and skin tissue involvement (Figure 1A) in GVHD, we began with the clinical evaluation of mice undergoing allogeneic hematopoietic stem cell transplants (HSCT) using the scoring system for skin (Methods) and our ocular clinical scoring system (Figure 1B) [15,16]. Five distinct donor-recipient strain combinations were used throughout these studies to assess MHC-matched (n = 3) and mismatched (n = 2) transplant outcomes (Table 1). Initially, an MHC-matched transplant
was performed using B6 (H2b) donors and C3H.SW (H2b) recipient mice, which result in ocular GVHD [14,15]. Notably, systemic clinical signs of GVHD are readily apparent 2–3 weeks post-HSCT in animals receiving both donor BM and splenic T cells compared to recipients of BM only (Figure 2A). Following the development of systemic acute GVHD at approximately 3 weeks post-HSCT, changes were observed in both the skin and eye. Skin changes are reflected by an increased clinical score (ruffling, alopecia, and scabbing) and histological changes (thickening and inflammatory infiltrate). Eye findings included eyelid edema and the corneal clinical epithelial haze and keratopathy with histologic changes demonstrating epithelial thickening and infiltration (Figure 2B–D). Notably, the kinetics of eyelid involvement paralleled that observed in recipient skin (Figure 2B vs. Figure 2D). Interestingly, corneal clinical changes were observed later, 5–7 weeks post-HSCT.

**Figure 1.** Schematic and clinical scoring features of ocular and cutaneous involvement in graft vs. host disease. (A) Clinical photos from patient with GVHD with corneal keratopathy (as demonstrated with fluorescein staining) and sclerodermal skin changes characterized by the thickening and induration of the cutaneous epithelium. (B) Schematic of ocular changes characterized by lid swelling and closure and skin pathology as demonstrated by alopecia and decreased skin integrity and fur texture in pre-clinical HSCT models. (C) Skin and ocular scoring system parameters used in the GVHD models were adapted from Perez et al. [15] and Cooke et al. [27].

**Table 1.** Transplants performed to assess/examine the relationship between skin and eye involvement post-allo HSCT.

| Donor Strain | Recipient Strain | Genetic Disparity |
|--------------|------------------|------------------|
| B6 (H2b)     | C3H.SW (H2b)     | MHC Matched 1    |
| LP/J (H2b)   | B6 (H2b)         | MHC Matched      |
| B10.D2 (H2d) | BALB/c (H2d)     | MHC Matched      |
| B6 (H2b)     | B10.BR (H2k)     | MHC Mismatched 2 |
| B6 (H2b)     | BALB/c (H2d)     | MHC Mismatched   |

1 Major histocompatibility matched, minor histocompatibility mismatched transplants. 2 Major histocompatibility mismatched, minor histocompatibility mismatched transplants.
We then examined additional MHC-matched donor-recipient strain combinations. First, B10.D2 (H2d) → BALB/c (H2d) transplants were investigated. Eyelid swelling as well as corneal keratopathy and skin changes (i.e., ruffling, alopecia, and scabbing) were again apparent in the recipients of donor BM and T cells (Figure 3A).

Table 1. Transplants performed to assess/examine the relationship between skin and eye involvement post-allo HSCT.

| Donor Strain | Recipient Strain | Genetic Disparity |
|--------------|------------------|------------------|
| B6 (H2b)    | C3H.SW (H2b)     | MHC Matched 1    |
| LP/J (H2b)  | B6 (H2b)         | MHC Matched      |
| B10.D2 (H2d)| BALB/c (H2d)     | MHC Matched      |
| B6 (H2b)    | B10.BR (H2k)     | MHC Mismatched 2 |
| B6 (H2b)    | BALB/c (H2d)     | MHC Mismatched   |

1 Major histocompatibility matched, minor histocompatibility mismatched transplants. 2 Major histocompatibility mismatched, minor histocompatibility mismatched transplants.

Figure 2. Correlation of the development of ocular and skin GHVD in MHC-matched HSCT recipients. Correlation between cutaneous and ocular tissue involvement (plotted as mean and SD) following MHC-matched (B6 → C3H.SW) allogeneic transplant of donor bone marrow (T-cell depleted—TCD-BM) +/− T cells. Mice (n = 5/group) were transplanted with donor B6 TCD-BM alone did not exhibit detectable changes in the skin or ocular compartment. Recipients of B6 TCD-BM + T cells initially exhibited a systemic clinical score (A) and then cutaneous GVHD (B) and ocular GVHD involving the cornea and lids (C,D). The data in this figure is representative of an individual experiment. This donor/recipient combination has been routinely transplanted in our laboratory and systemic and ocular GVHD changes were reported in several published studies [14,15,21].
The histological examination demonstrated epithelial corneal thickening (blue arrow) and corneal stromal thinning (black arrow) in animals undergoing GVHD, which was not observed in control BM only transplanted mice (Figure 3B). The histological examination of the skin (Figure 3B: lower panels) showed epidermal layer thickening, dermal thickening with extensive collagen infiltration of the underlying fat layer, and loss of hair follicles in recipients of T cells undergoing GVHD, but not in recipients of BM only controls. To quantitate these changes, we developed a scoring criterion to assess epithelia thickening and corneal stromal thinning as described (Methods).

Figure 3. Development of ocular and skin GVHD following HSCT in an MHC-matched donor/recipient strain combination. Transplants were performed using donor B10.D2 (H2d) bone marrow +/- spleen cells containing T cells into BALB/c (H2d) recipients. (A) Clinical examination of animals approximately 5-weeks post-HSCT revealed that mice receiving donor T cells exhibited ruffled fur, alopecia, and scabbing in the ears. In the ocular compartment, edema with eyelid swelling was observed. This analysis is based on an n = 4/group (animals meeting the inclusion criteria, i.e., animals for which we had both skin and eye histology allowing analysis) for BMO and BM + T cells. (B), upper panels) The histological examination of the cornea demonstrated epithelial thickening (blue arrow) and corneal stromal thinning (black arrow) in animals undergoing GVHD but not in control transplanted mice. (B), lower panels) The histological examination of the skin comparing bone-marrow only control (B, lower left panel) with GVHD samples (B, lower right panel) revealed epidermal layer thickening, dermal thickening with extensive collagen infiltration of the underlying fat layer, and loss of hair follicles. (C) Significant differences were observed between control and GVHD mice in the epidermal thickening in the ocular and skin compartments ((C): upper panels). Analysis of the total histological ocular and skin scores ((C): lower panels). BM + T cells (n = 4/group) and BMO (n = 4/group). * denotes p value < 0.05.
The results indicated significant increases in corneal as well as skin epithelial thickening in mice undergoing GVHD (Figure 3C, upper panels) as well as significant increases in their total ocular and skin scores (Figure 3C, lower panels). Although recipients of BM and T cells exhibited other histological trends, such as decreased corneal stromal thickness and higher corneal epithelial vacuolization, differences compared to recipients of BM alone did not attain statistical significance (Supplemental Figure S1). MHC-matched transplants were also performed utilizing a third donor-recipient strain combination, i.e., LPJ (H2b) → B6 (H2b) recipients. In the manner of the other MHC-matched models, ocular and cutaneous clinical changes were clearly observed after 1 month involving lid edema, conjunctival swelling, and keratopathy as well as fur changes and skin scabbing, respectively (Supplemental Figure S2).

3.2. Analysis of Ocular and Cutaneous Changes following MHC-Mismatched Allogeneic Hematopoietic Stem Cell Transplants

MHC-mismatched donor/recipient aHSCT was performed using a model reported to reflect chronic GVHD as indicated by changes in a wide variety of recipient compartments, including the lung and mucosal and lymphoid tissues [24]. C57BL/6 (H2b) bone marrow +/− 6 × 10^4 T cells were administered into B10.BR (H2k) recipients (Figure 4). Two independent experiments (n = 5/group) were performed, and animals were examined at ~1 month (28 days) and ~2 months (56 days) post-HSCT. Mild clinical changes were typically detected in recipients by 2 months post-HSCT were present in the skin (ruffling) and eyes (mild lid edema) of recipients of bone marrow plus T cells (Figure 4A). Moreover, histological analyses of the cornea and skin indicated minimal epithelial thickening and quantification of scoring confirmed there was not statistical significance versus control recipients (Figure 4C). In total, these findings again indicated a positive correlation between the skin and eye compartments based on significant (Figure 3) or mild (Figure 4) involvement in these preclinical transplant models (Figure 5).

Next, to further test this correlation, transplants were performed with BALB/c (H2d) recipients of donor B6 (H2b) BM +/− T cells using an acute model of GVHD (Figure 6). The examination of eye and skin in these mice revealed that, following allogeneic BM + T cell transplant, mice with no or low (less than or equal to 1.0) clinical eyelid scores had no skin score as well (Figure 6A). We have previously utilized PTCy post-transplant (PTCy) for GVHD prophylaxis in pre-clinical HSCT models [20,23]. In this study, PTCy was administered for GVHD prophylaxis in this MHC-mismatched B6 → BALB/c transplant. Similar to the non-PTCy treated animals, the assessment of eye and skin in these recipients revealed that, following allogeneic BM + T cell transplant, mice with no or low clinical eyelid scores had no skin score (closed symbols, Figure 6B). Notably, some animals receiving PTCy did develop GVHD and, in all but one of these mice, eye scores were significantly greater and skin scores were also elevated (open symbols, Figure 6B). One mouse treated with PTCy did exhibit significant eye scores without noticeable skin changes (open upward triangle, Figure 6B). Notably, we also performed transplants in this model in which animals received T cells from donor B6 mice and were then administered TNFRSF25 and CD25 agonists, which we have previously reported stimulate the Treg compartment [22,28] (Figure 6C). None of these recipients exhibited strong eye or skin scores (all scores ≤1, Figure 6C). These data also support the notion that eyelid compared to skin scoring is a more sensitive indicator of ongoing GVHD and, importantly, a positive correlation was observed between changes detected in the eye and skin compartments [15].
were not significantly different between recipients of BM only vs. BM + T cells. ns denotes p
values that were >0.05.

Figure 4. Development of ocular and skin GVHD following HSCT in an MHC-mismatched
donor/recipient strain combination. Transplants were performed using donor B6 (H2b) bone mar-
row +/- spleen cells containing T cells into B10.BR (H2k) recipients. (A) Clinical examination of
animals approximately 8-weeks post-HSCT revealed marginal clinical with virtually no edema and
eyelid swelling in the ocular compartment in mice receiving BM only or BM + T cells. Only mice with
both ocular and skin histologic samples were included. This led to n = 4/group in both BM + T cells
and BMO groups. (B) The histological examination of the cornea did not identify epithelial thickening
in the cornea or skin or corneal stromal thinning. Data presented represent individual B10.BR ani-
mals at Day 56. (C) The analysis of representative mice found the total histological ocular and skin scores
were not significantly different between recipients of BM only vs. BM + T cells. ns denotes p values
that were >0.05.

Figure 5. Correlation analysis comparing skin disease severity index with that of the ocular severity
index at 8-weeks post-HSCT. Summary of results and comparisons of the skin disease variables and
skin severity scores for the MHC-matched (B10.D2 → BALB/c), MHC-mismatched (B6 → B10.BR)
GVHD models, and controls (bone marrow only). This included 4 mice from each GVHD model
(n = 8 total) When the total ocular disease score index for each mouse was plotted against the total
skin disease index, a significant correlation between skin and eye disease was identified: coefficient
of 0.6037 (p-value: 0.0253).
There have been several drugs recently approved for use in patients with GVHD, including ibrutinib, ruxolitinib, and most recently, belumosudil [29–33]. Ruxolitinib has led to a diminishment of treatment-related morbidity, reduction of GVHD, and prolonged patient survival [30–32]. Nonetheless, ocular GVHD occurs in the majority of patients with chronic GVHD following aHSCT, resulting in damage to ocular tissues, dry eye disease, and keratopathy [6–10]. In this context, it is interesting that cutaneous manifestations are the most common—and frequently the presenting—clinical sign of GVHD and involve rash, erythroderma, and blisters, and scleroderma-like lesions [34,35]. Notably, the use of murine experimental aHSCT models has observed ophthalmic manifestations, such that analysis of potential correlation with dermatologic changes can be investigated [14–16]. It is well established that different pre-clinical mouse HSCT models as observed in patients after aHSCT exhibit varying levels of GVHD severity in different target compartments, including the gastrointestinal tract, lungs, as well as the eye and skin [36–39]. Since both the ocular and skin compartments contain an important epithelial cell layer directly exposed to environmental stresses, we considered the notion that GVHD might similarly affect both of these tissues and employed pre-clinical HSCT to examine if any correlation could be identified.

We first examined multiple models of experimental allogeneic MHC-matched HSCT that represent the most common aHSCT performed in our patients to assess ocular and skin changes and identified a consistent correlation between ocular and cutaneous involvement accompanying GVHD. Additionally, we exploited our group’s experience across multiple institutions and performed experimental MHC-mismatched aHSCT to determine if this correlation also occurred. We detected a “positive” correlation, i.e., when GVHD-induced ocular changes were detected in these complete MHC-mismatched recipients, changes in...
the cutaneous compartment were typically observed. In contrast, when low or no ocular involvement was detected, minimal skin changes were observed. Secondly, we observed that examination of the MHC-mismatched H2b (B6) into H2d (BALB/c) model demonstrated a correlation regardless of the extent of eye involvement, hence when there was a low eye involvement, there was a low skin involvement, and when high eye involvement was detected, there was a correspondingly high skin score. Notably, to more rigorously analyze clinical changes across the skin and cornea, histological samples from the bone marrow only controls and that of the diseased GVHD mice (both MHC-matched and mismatched models) were assessed, comparing the skin disease severity index with that of the ocular severity index (Figure 5). When the total ocular disease score index for each mouse was plotted against the total skin disease index, a significant correlation between skin and eye disease was identified. Overall, these findings suggest underlying GVHD-inducing pathological immune/inflammatory mechanisms may be shared between the eye and skin tissues.

Lastly, to directly test the correlation between ocular and cutaneous correlation, we performed interventional experiments by manipulating the T-cell compartment in vivo to assess cutaneous and ocular responses. Interestingly, when PTCy was employed for GVHD prophylaxis, we observed a predominant diminution of systemic GVHD (data not shown) in most animals, as anticipated [20,21]. However, GVHD was observed in some animals with both ocular and cutaneous clinical manifestations of GVHD. We do not know and cannot predict these outcomes, but posit that some animals did develop GVHD resulting from incomplete deletion and/or regulation of donor anti-host alloreactive T cells specific for MHA and/or non-MHC encoded minor transplantation antigens. Our prior work demonstrated that Treg cells are required for effective PTCy prophylaxis of GVHD [21]. Hence, when Treg cells were not present, the emergence of GVHD after cyclophosphamide presence at D.3 and 4 strongly suggests some donor T cells with anti-host reactivity do persist and need to be regulated, i.e., suppressed to prevent GVHD [21]. Notably, in mice in which we administered agonists to expand Treg cells post-transplant and after cyclophosphamide treatment, very mild systemic GVHD was detected; however, a correlation was observed between ocular (mild) and skin (mild) involvement. It should be noted that two of the animals treated with PTCy did not show a correlation between the eye and skin (Figure 6B). Interestingly, in these animals, the eyelid showed a significant score without skin involvement, suggesting that the eyelid may be a more sensitive indicator of GVHD, as we previously reported [15]. Overall, we speculate that diminishment of cGVHD following PTCy treatment in patients will predominantly reflect the skin [34,35] and ocular correlations we identified, and therefore, in recipients with a diminished cutaneous GVHD, a diminished oGVHD will be observed. Moreover, although additional studies are required, we can speculate the potential generalizability of these findings onto other prophylactic regimens in GVHD (i.e., anti-thymocyte globulin, G-CSF, etc.) at ameliorating GVHD resulting from shared immune mechanisms across different tissues [40].

To our knowledge, the studies we are reporting represent the initial observations using experimental allo-hematopoietic stem cell transplant models selectively examining two target tissues affected by GVHD, the eye and skin. While the sample sizes for this first study are modest, we remain confident in the results and the associations observed. Moreover, we anticipate the work will stimulate additional studies that will continue to address the hypothesis that similar immune mechanisms are responsible for GVHD induced ocular and skin manifestations. In total, using multiple independent and well-established pre-clinical mouse aHSCT models, regardless of the donor and recipient strains employed, we consistently observed a correlation between the ophthalmic and cutaneous compartments in recipients undergoing GVHD. Accordingly, when ophthalmic involvement was identified, skin alterations also were present in the recipients (i.e., “positive correlation”) and, in contrast, when ophthalmic changes did not occur, skin involvement was also not identified. Therefore, not unlike clinical aHSCT in which complications associated with GVHD vary, the findings in this study suggest that, in patients with GVHD, a similar correlation
may exist in the clinical setting. Therefore, when skin involvement is present in aHSCT recipients with GVHD, the evaluation of the ocular surface by an ophthalmologist could be of potential value.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/ijms23010184/s1.

Author Contributions: Conceptualization, R.B.L., B.R.B. and V.L.P.; funding acquisition, R.B.L., B.R.B. and V.L.P.; investigation, H.M.M., C.O.L., E.J.S., D.L., S.D., R.F., J.D., H.B., M.Z. and K.P.; project administration, R.B.L., B.R.B. and V.L.P.; resources, R.B.L., B.R.B. and V.L.P.; supervision, R.B.L.; writing—original draft, R.B.L. and V.L.P.; writing—review and editing, R.B.L., H.M.M., C.O.L., B.R.B. and V.L.P. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by funds from the NIHRO1 EY024484-06, R01EY030283-01 (RL and VLP); R41AI149916-01, and SRA from Heat Biologics, Inc. (RL); Unrestricted grant from Research to Prevent Blindness Duke (VLP), Duke NIH-NEI P30-EY005722-35 (VLP); Stephen and Frances Foster Research Endowment (VLP), Sylvester Comprehensive Cancer Center. RL and the funder bodies were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.

Institutional Review Board Statement: These are animal studies and as we stated in the Methods: “All animal studies were conducted according to protocols approved by the University of Miami, Minnesota, and Duke University’s Animal Care and Use Committees, and in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.” Protocol numbers: 19-114-LF Date of Approval: 6/19/2019; 16-232: date of Approval: 11/2/2017.

Informed Consent Statement: Not applicable.

Data Availability Statement: To share data throughout the research community, and all can benefit from the tools, reagents and models generated at the institutions, pending third parties rights, the institutions will transfer materials to outside researchers under a Material Transfer Agreements (MTAs) generated and monitored by the University of Miami and Duke Technology Transfer Offices. Such MTAs will be made with no more restrictive terms than the Simple Letter Agreement (SLA) to non-profit institutions or the Uniform Biological Material Transfer Agreement (UMBTA) to for-profit ones. This publication also functions as a means to share knowledge obtained from our studies.

Acknowledgments: We are grateful to the Sylvester Comprehensive Cancer Center Flow Cytometry Core for their excellent assistance with flow cytometry and cell sorting, and the staff at the Division of Veterinary Resources at the University of Miami Miller School of Medicine for their outstanding animal maintenance and care of the valuable mice used in these studies. The authors also want to acknowledge the help of Jose Echegaray and Liwen Lin, PhD. for the experimental materials and laboratory operations in the preparation of the manuscript.

Conflicts of Interest: RBL is a compensated consultant/advisory board member for and equity holder in Heat Biologics. RL and VLP received sponsored research funding from Heat Biologics, Inc., and Alcon, respectively. BRB receives remuneration as an advisor to Magenta Therapeutics and Bluerock Therapeutics; research funding from BlueRock Therapeutics, Rheos Medicines, Equilibre biopharmaceuticals, Carisma Therapeutics, Inc., and is a co-founder of Tmunity Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

References
1. Li, H.W.; Sykes, M. Emerging concepts in haematopoietic cell transplantation. Nat. Rev. Immunol. 2012, 12, 403–416. [CrossRef]
2. Martin, P.J.; Inamoto, Y.; Carpenter, P.A.; Lee, S.J.; Flowers, M.E. Treatment of chronic graft-versus-host disease: Past, present and future. Korean J. Hematol. 2011, 46, 153–163. [CrossRef]
3. Ferrara, J.L.; Levine, J.E.; Reddy, P.; Holler, E. Graft-versus-host disease. Lancet 2009, 373, 1550–1561. [CrossRef]
4. Blazar, B.R.; Murphy, W.J.; Abedi, M. Advances in graft-versus-host disease biology and therapy. Nat. Rev. Immunol. 2012, 12, 443–458. [CrossRef] [PubMed]
5. Newman, R.G.; Ross, D.B.; Barreras, H.; Herretes, S.; Podack, E.R.; Komanduri, K.V.; Perez, V.L.; Levy, R.B. The allure and peril of hematopoietic stem cell transplantation: Overcoming immune challenges to improve success. Immunol. Res. 2013, 57, 125–139. [CrossRef]
6. Riemens, A.; Boome, L.T.; Imhof, S.; Kuball, J.; Rothova, A. Current insights into ocular graft-versus-host disease. Curr. Opin. Ophthalmol. **2010**, *21*, 485–494. [CrossRef] [PubMed]

7. Hessen, M.; Akpek, E.K. Ocular graft-versus-host disease. Curr. Opin. Allergy Clin. Immunol. **2012**, *12*, 540–547. [CrossRef]

8. Tabbara, K.F.; Al-Ghamdi, A.; Al-Mohareb, F.; Ayas, M.; Chaudhri, N.; Al-Sharif, F.; Al-Zahrani, H.; Mohammed, S.Y.; Nassar, A.; Aljurf, M. Ocular Findings after Allogeneic Hematopoietic Stem Cell Transplantation. *Ophthalmology* **2009**, *116*, 1624–1629. [CrossRef] [PubMed]

9. Hirst, L.W.; Jabs, D.A.; Tutschka, P.J.; Green, W.R.; Santos, G.W. The Eye in Bone Marrow Transplantation. I. Clinical study. *Arch. Ophthalmol.* **1983**, *101*, 580–584. [CrossRef]

10. Franklin, R.M.; Kenyon, K.R.; Tutschka, P.J.; Saral, R.; Green, W.R.; Santos, G.W. Ocular Manifestations of Graft-vs-Host Disease. *Ophthalmology* **1983**, *90*, 4–13. [CrossRef]

11. Na, K.-S.; Yoo, Y.-S.; Mok, J.W.; Lee, J.W.; Joo, C.-K. Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. **2015**, *50*, 1439–1446. [CrossRef]

12. Lamery, F.-J.; Lundy, F.; Al-Hashimi, I. Sjögren’s syndrome: A condition with features of chronic graft-versus-host disease: Does duct cell adhesion or permeability play a role in pathogenesis? *Med. Hypotheses* **2004**, *62*, 825–829. [CrossRef] [PubMed]

13. Marcellus, D.C.; Altomonte, V.L.; Farmer, E.R.; Horn, T.D.; Freemer, C.S.; Grant, J.; Vogelsang, G.B. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. *Blood* **1999**, *93*, 66–70. [CrossRef]

14. Herretes, S.; Ross, D.B.; Duffort, S.; Barreras, H.; Yaohong, T.; Saeed, A.M.; Murillo, J.C.; Komanduri, K.V.; Levy, R.B.; Perez, V.L. Recruitment of Donor T Cells to the Eyes During Ocular GVHD in Recipients of MHC-Matched Allogeneic Hematopoietic Stem Cell Transplants. *Investig. Ophthalmol. Vis. Sci.* **2013**, *56*, 2348–2357. [CrossRef] [PubMed]

15. Perez, V.L.; Barsam, A.; Duffort, S.; Uribeta, M.; Barreras, H.; Lightbourn, C.; Komanduri, K.V.; Levy, R.B. Novel Scoring Criteria for the Evaluation of Ocular Graft-versus-Host Disease in a Preclinical Allogeneic Hematopoietic Stem Cell Transplantation Animal Model. *Biol. Blood Marrow Transplant.* **2016**, *22*, 1765–1772. [CrossRef]

16. Perez, R.L.; Perez-Simon, J.A.; Caballero-Velazquez, T.; Flores, T.; Carrancio, S.; Herrero, C.; Blanco, B.; Gutierrez-Cosio, S.; Cañete-Campos, C.; Gonzalez, F.C.; et al. Limbus Damage in Ocular Graft-versus-Host Disease. *Biol. Blood Marrow Transplant.* **2011**, *17*, 270–273. [CrossRef] [PubMed]

17. Inagaki, E.; Ogawa, Y.; Matsumoto, Y.; Kawakita, T.; Shimmura, S.; Tsubota, K. Four cases of corneal perforation in patients with chronic graft-versus-host disease. *Mol. Vis.* **2011**, *17*, 959–966. [PubMed]

18. Kim, S.K. Update on ocular graft versus host disease. *Curr. Opin. Ophthalmol.* **2006**, *17*, 344–348. [CrossRef] [PubMed]

19. Dietrich-Ntoukas, T.; Cursiefen, C.; Westekemper, H.; Eberwein, P.; Reinhard, T.; Bertz, H.; Nepp, J.; Lawitschka, A.; Heiligenhaus, A.; Seitz, B.; et al. Diagnosis and Treatment of Ocular Chronic Graft-Versus-Host Disease: Report From the German–Austrian–Swiss Consensus Conference on Clinical Practice in Chronic GVHD. *Cornea* **2012**, *31*, 299–310. [CrossRef]

20. Wolf, D.; Bader, C.S.; Barreras, H.; Copsel, S.; Pfeiffer, B.J.; Lightbourn, C.O.; Altman, N.H.; Komanduri, K.V.; Levy, R.B. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models. *JCI Insight* **2018**, *3*. [CrossRef] [PubMed]

21. Ganguly, S.; Ross, D.B.; Panoskialitis-Mortari, A.; Kanakry, C.G.; Blazar, B.R.; Levy, R.B.; Luznik, L. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. *Blood* **2014**, *124*, 2131–2141. [CrossRef] [PubMed]

22. Wolf, D.; Barreras, H.; Bader, C.S.; Copsel, S.; Lightbourn, C.O.; Pfeiffer, B.J.; Altman, N.H.; Podack, E.R.; Komanduri, K.V.; Levy, R.B. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation. *Biol. Blood Marrow Transplant.* **2017**, *23*, 757–766. [CrossRef] [PubMed]

23. Lightbourn, C.O.; Wolf, D.; Copsel, S.N.; Wang, Y.; Pfeiffer, B.J.; Barreras, H.; Bader, C.S.; Komanduri, K.V.; Perez, V.L.; Levy, R.B. Use of Post-transplant Cyclophosphamide Treatment to Build a Tolerance Platform to Prevent Liquid and Solid Organ Allograft Rejection. *Front. Immunol.* **2021**, *12*, 636789. [CrossRef] [PubMed]

24. Flynn, R.; Du, J.; Veenstra, R.G.; Reichenbach, D.K.; Panoskialitis-Mortari, A.; Taylor, P.A.; Freeman, G.J.; Serody, J.S.; Murphy, W.J.; Munn, D.H.; et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. *Blood* **2014**, *123*, 3988–3998. [CrossRef] [PubMed]

25. Radojcic, V.; Pletneva, M.A.; Yen, H.-R.; Ivcevic, S.; Panoskialitis-Mortari, A.; Gilliam, A.C.; Drake, C.G.; Blazar, B.R.; Luznik, L. STAT3 Signaling in CD4+ T Cells Is Critical for the Pathogenesis of Chronic Sclerodermatous Graft-Versus-Host Disease in a Murine Model. *J. Immunol.* **2010**, *184*, 764–774. [CrossRef]

26. Anderson, B.E.; McNiff, J.; Yan, J.; Doyle, H.; Mamula, M.; Shlomchik, M.; Shlomchik, W.D. Memory CD4+ T cells do not induce graft-versus-host disease. *Clin. Investig.* **2003**, *112*, 101–108. [CrossRef]

27. Cooke, K.; Kobzik, L.; Martin, T.; Brewer, J.; Delmonte, J.J.; Crawford, J.; Ferrara, J. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. *Blood* **1996**, *88*, 3230–3239. [CrossRef] [PubMed]

28. Copsel, S.; Wolf, D.; Kale, B.; Barreras, H.; Lightbourn, C.O.; Bader, C.S.; Alperstein, W.; Altman, N.H.; Komanduri, K.V.; Levy, R.B. Very Low Numbers of CD4+ FoxP3+ Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation/Functional Profile and Suppress GVHD in a Preclinical Model. *Biol. Blood Marrow Transplant.* **2018**, *24*, 1788–1794. [CrossRef]
29. Cutler, C.S.; Koreth, J.; Ritz, J. Mechanistic approaches for the prevention and treatment of chronic GVHD. *Blood* 2017, 129, 22–29. [CrossRef]

30. Harrison, C.; Kiladjian, J.-J.; Al-Ali, H.K.; Gisslinger, H.; Waltzmann, R.; Stallbovskaya, V.; McQuitty, M.; Hunter, D.S.; Levy, R.; Knoops, L.; et al. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. *N. Engl. J. Med.* 2012, 366, 787–798. [CrossRef]

31. Spoerl, S.; Mathew, N.R.; Bscheider, M.; Schmitt-Graeff, A.; Chen, S.; Mueller, T.; Verbeek, M.; Fischer, J.; Otten, V.; Schimckl, M.; et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. *Blood* 2014, 123, 3832–3842. [CrossRef] [PubMed]

32. Jagasia, M.; Perales, M.-A.; Schroeder, M.A.; Ali, H.; Shah, N.N.; Chen, Y.-B.; Fazal, S.; Dawkins, F.W.; Arbushites, M.C.; Tian, C.; et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): A multicenter, open-label phase 2 trial. *Blood* 2020, 135, 1739–1749. [CrossRef] [PubMed]

33. Jagasia, M.; Lazaryan, A.; Bachier, C.R.; Salhotra, A.; Weisdorf, D.J.; Zoghi, B.; Essell, J.; Green, L.; Schueller, O.; Patel, J.; et al. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. *J. Clin. Oncol.* 2021, 39, 1888–1898. [CrossRef]

34. Jacobsohn, D.A.; Kurland, B.F.; Pidala, J.; Inamoto, Y.; Chai, X.; Palmer, J.M.; Arai, S.; Arora, M.; Jagasia, M.; Cutler, C.; et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: Results from the Chronic GVHD Consortium. *Blood* 2012, 120, 2545–2552. [CrossRef]

35. Martires, K.J.; Baird, K.; Steinberg, S.M.; Grkovic, L.; Joe, G.O.; Williams, K.M.; Mitchell, S.A.; Datiles, M.; Hakim, F.T.; Pavletic, S.Z.; et al. Sclerotic-type chronic GVHD of the skin: Clinical risk factors, laboratory markers, and burden of disease. *Blood* 2011, 118, 4250–4257. [CrossRef] [PubMed]

36. Kitko, C.L.; Pidala, J.; Schoemans, H.M.; Lawitschka, A.; Flowers, E.W.; Tkaczyk, E.; Farhadfar, N.; Jain, S.; Steven, P.; et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. *Transplant. Cell. Ther.* 2021, 27, 545–557. [CrossRef] [PubMed]

37. Wolff, D.; Radojcic, V.; Lafyatis, R.; Cinar, R.; Rosenstein, R.K.; Cowen, E.W.; Cheng, G.-S.; Sheshadri, A.; Bergeron, A.; Williams, K.M.; et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. *Transplant. Cell. Ther.* 2021, 27, 817–835. [CrossRef]

38. Zeiser, R.; Blazar, B.R. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. *N. Engl. J. Med.* 2017, 377, 2565–2579. [CrossRef]

39. Thomas, E.D.; Strob, R.; Clift, R.A.; Fefer, A.; Johnson, F.L.; Neimean, P.E.; Lerner, K.G.; Glucksberg, H.; Buckner, C.D. Bone-marrow transplantation (second of two parts). *N. Engl. J. Med.* 1975, 292, 895–902. [CrossRef]

40. Wang, Y.; Wu, D.-P.; Liu, Q.-F.; Xu, L.-P.; Liu, K.-Y.; Zhang, X.-H.; Yu, W.-J.; Xu, Y.; Huang, F.; Huang, X.-J. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. *J. Hematol. Oncol.* 2019, 12, 1–9. [CrossRef] [PubMed]